Clinical Trials Browser

Completed × encorafenib × Clear all

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 1 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT03915951 2025-11-17

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05304546 2025-07-22

MK3475-C01

Phase 2 Completed

Melanoma, Neoplasms

NCT03898908 2025-05-21

EBRAIN-MEL

Phase 2 Completed

48 enrolled 24 charts

CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT05004350 2025-04-15

NAUTICALCRC

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01894672 2024-07-16

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Phase 2 Completed

7 enrolled 9 charts

Melanoma

NCT02631447 2024-06-07

SECOMBIT

Phase 2 Completed

Melanoma

NCT01543698 2024-03-13

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Phase 1/2 Completed

189 enrolled 44 charts

Other solid neoplasm

Solid Tumors Harboring a BRAF V600 Mutation

NCT02159066 2024-03-05

LOGIC-2

Phase 2 Completed

158 enrolled 40 charts

Melanoma

NCT03693170 2024-02-02

ANCHOR-CRC

Phase 2 Completed

95 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT02928224 2023-12-21

BEACON CRC

Phase 3 Completed

702 enrolled 82 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT02834364 2023-11-24

GMMG-BIRMA

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT02857270 2022-11-22

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Phase 1 Completed

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT02278133 2017-10-09

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Phase 1/2 Completed

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms